Grace Therapeutics, Inc.

NasdaqCM:GRCE Stock Report

Market Cap: US$31.4m

Grace Therapeutics Valuation

Is GRCE undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of GRCE when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate GRCE's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate GRCE's fair value for valuation analysis.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for GRCE?

Other financial metrics that can be useful for relative valuation.

GRCE key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenuen/a
Enterprise Value/EBITDA-0.9x
PEG Ration/a

Price to Book Ratio vs Peers

How does GRCE's PB Ratio compare to its peers?

The above table shows the PB ratio for GRCE vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PBEstimated GrowthMarket Cap
Peer Average8.5x
COCP Cocrystal Pharma
1.1x-14.4%US$17.6m
VYNE VYNE Therapeutics
0.6x-16.0%US$39.1m
ALTS ALT5 Sigma
4.7xn/aUS$30.5m
RANI Rani Therapeutics Holdings
27.4x25.2%US$130.3m
GRCE Grace Therapeutics
0.5x43.2%US$31.4m

Price-To-Book vs Peers: GRCE is good value based on its Price-To-Book Ratio (0.5x) compared to the peer average (8.5x).


Price to Earnings Ratio vs Industry

How does GRCE's PE Ratio compare vs other companies in the US Pharmaceuticals Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a23.6%
n/an/an/a
No. of CompaniesPB048121620

Fetching data

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a23.6%
n/an/an/a
No more companies

Price-To-Book vs Industry: GRCE is good value based on its Price-To-Book Ratio (0.5x) compared to the US Pharmaceuticals industry average (1.6x).


Price to Book Ratio vs Fair Ratio

What is GRCE's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

GRCE PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio0.5x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate GRCE's Price-To-Book Fair Ratio for valuation analysis.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst GRCE forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$3.14
US$10.62
+238.7%
19.4%US$12.49US$7.75n/a3
Oct ’25US$3.01
US$9.99
+232.0%
20.0%US$11.99US$8.00n/a2
Sep ’25US$2.62
US$9.01
+243.9%
33.5%US$12.03US$5.99n/a2
Aug ’25US$2.69
US$8.99
+234.3%
33.5%US$12.01US$5.98n/a2
Jul ’25US$2.92
US$8.99
+208.0%
33.5%US$12.01US$5.98n/a2
Apr ’25US$3.45
US$9.08
+163.2%
34.0%US$12.17US$5.99n/a2
Mar ’25US$3.44
US$9.08
+164.4%
34.0%US$12.17US$5.99n/a2
Jun ’24US$3.21
US$13.12
+308.7%
9.7%US$14.39US$11.85US$2.732
May ’24US$2.74
US$13.80
+403.7%
9.3%US$14.91US$12.00US$2.853
Apr ’24US$2.76
US$13.82
+400.7%
9.4%US$14.95US$11.99US$3.453
Mar ’24US$3.06
US$13.82
+350.9%
9.4%US$14.95US$11.99US$3.443
Feb ’24US$3.96
US$13.83
+249.3%
9.5%US$15.05US$12.02US$2.453
Jan ’24US$3.01
US$13.83
+360.1%
9.5%US$15.05US$12.02US$2.893

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.


Discover undervalued companies